

Drug Dosage Increase for a previously approved Prior Authorization Drug

This form is intended to obtain information required to review a drug dose that is not within Health Canada's recommended guidelines.

IMPORTANT: Please answer all questions. Your claim assessment may be delayed if this form is incomplete or contains errors.

Any costs incurred for the completion of this form are the responsibility of the plan member/patient.

Dout 1 Dlan Mambay Information (places print)					
Part 1 Plan Member Information (please print)					
Plan Member:		Patient Name:			
Plan Name:	Plan Number:		Plan Member ID Number:		
Patient Date of Birth (DD/MM/YYYY):	Address (number, street, city, province, postal code):				
Please indicate preferred contact number and if the	ere are any times when t	telephone contact with yo	u about your claim would be most convenient.		
May we contact you by email? (Note that some correspondence may still need to be sent by regular mail).					
Yes No If yes, please provide email add	dress:	, ,			
Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of					
assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have					
questions about Canada Life's personal infor			respect to service providers), refer to		
www.canadalife.com or write to Canada Life's Chief Compliance Office.					
I authorize Canada Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of					
government benefits or patient assistance pr	ograms or other bene	efits programs, other or	ganizations, or service providers working		
with Canada Life or any of the above, located inside or outside Canada, to exchange personal information when relevant and					
necessary for these purposes. I understand that personal information may be subject to disclosure to those authorized under					
applicable law within or outside Canada.					
I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan.					
I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay					
or denial of my claim. Canada Life reserves the right to audit the information provided on this form at any time and this consent					
extends to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.					
If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information					
and for Canada Life to use and disclose it as set out above.					
I certify that the information given is true, correct, and complete to the best of my knowledge. Failure to provide true, correct and					
complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other					
appropriate action.					
Plan Member's signature:		Date:			



Physician's Questionnaire

Please have Part 2 completed by your prescribing physician.

Parl	2 Physician's Information (please print)					
	e of prescribing physician (please print):					
Spec	ialty:					
Addre	ess (number, street, city, province, postal code):					
Telep	hone Number (including area code):	Fax Number	(including area code):			
Prior	Authorization Drug:	Medical Cor	ndition:			
1.	Provide the date this drug was first started (DD/MM/YYYY):					
Provide the starting dose and frequency for this drug:						
3.	3. Patient's current weight: kg Date Determined (DD/MM/YYYY)					
	Dose and/or frequency requested:					
5.	5. Medical rationale for the dose and/or frequency increase:					
	Please provide supporting lab results and/or investigative reports					
	(Genetic test results are not required)					
6.	6. Has therapeutic drug monitoring (TDM) testing been performed? ☐ Yes ☐ No ☐ Not applicable					
	Please submit lab results					
	If no, provide rationale:					
7.	7. Is there evidence supporting the effectiveness and safety for the requested drug's dose and/or frequency?					
	☐ Yes ☐ No ☐ Not applicable					
	Provide clinical literature/studies to support the request, such as:					
	 At least two Phase II or two Phase III clinical trials showing consistent results of efficacy Published evidence-based guideline recommendations 					
Attach supporting documentation						
I cert	ify that the information provided is true, correct, and complete.					
Phys	cian's signature:		Date:			
Licer	se Number:					
	mportant to provide the requested information in detail to help avoic mation form can be returned to Canada Life by mail, fax or email.	d delay in asse	essing claims for the above drug. The completed Request for			
Note	: As email is not a secure medium, any person with concerns about uraged to submit their form by other means.	their medical	information being intercepted by an unauthorized party is			
Mail t	o: The Canada Life Assurance Company Drug Claims Management	Fax to:	The Canada Life Assurance Company Fax 1-204-946-7664			

Attention: Drug Claims Management

Drug Claims Management

PO Box 6000

Winnipeg MB R3C 3A5

cldrug.services@canadalife.com Attention: Drug Claims Management Email to: